Evidence map›Paper›PMID 41721122›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Metabolomics and bioinformatics study of baicalin in treating pulmonary fibrosis.

Tiancheng Meng, Tianwei Meng, Hong Chang, Hongyu Meng

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tiancheng Meng *Beijing University of Chinese Medicine, Beijing, 100007, China.
Tianwei Meng *Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150006, China.
Hong ChangDepartment of Pharmacy, Baotou Medical College, Baotou, 014040, Inner Mongolia, China. changhong_cool@163.com.
Hongyu MengBeijing University of Chinese Medicine, Beijing, 100007, China. menghyhy@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) is a key pathological feature of various lung diseases, highlighting the urgent need for precise diagnostic biomarkers and effective therapeutic agents. This study aims to elucidate the mechanism of baicalin in treating PF using metabolomics and bioinformatics approaches. A PF rat model was established by bleomycin injection, with lung tissue pathology assessed at weeks 1, 3, and 5. After model establishment, rats were administered baicalin by gavage at doses of 25, 50, and 100 mg·kg⁻

Indexed as

FlavonoidsMetabolomicsPulmonary FibrosisAnimalsBiomarkersBleomycinComputational BiologyDisease Models, AnimalLungMaleRatsRats, Sprague-DawleybaicalinBiomarkersBleomycinFlavonoidsBaicalinBioinformaticsMechanism of actionPulmonary fibrosisUrine metabolomics

Identifiers

PMID41721122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.